cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5281/zenodo.15466292
title: ExoMiner++: Enhanced Transit Classification and a New Vetting Catalog for 2-Minute TESS Data

description: Summary

This data repository is associated with the work presented in paper "ExoMiner++: Enhanced Transit Classification and a New Vetting Catalog for 2-Minute TESS Data" .

Contents



exominerplusplus_catalog_unk_tces_s1-s67_tess-spoc-2min_complete_1-16-2025_1014.csv: vetting catalog of unlabeled (UNK) TESS SPOC 2-min TCEs for sector runs S1-S67 (included multi-sector runs) produced using the ExoMiner++ models trained for the experiment "TESS+Kepler" (see Table 6 in paper). A shorter catalog is available online here (TCEs with score < 0.1 are excluded due to memory constraints).

exominerplusplus_catalog_labeled_tces_s1-s67_tess-spoc-2min_complete_1-14-2025_1039.csv: catalog for the labeled TESS SPOC 2-min TCEs for sector runs S1-S67 (included multi-sector runs) dataset used to train the models in the experiment "TESS+Kepler" (see Table 6 in paper).

exominer_plusplus_architecture.png: image of ExoMiner++ architecture.

tfrecords_tess-spoc-2min_s1-s67_9-24-2024_1159.tar.xz: a compressed file of the TESS dataset used to train and evaluate the models in the paper (does not include the Kepler data). The examples are split across multiple files (aka shards) in TFRecord format. This dataset was used as source for the creation of the cross-validation dataset used in the paper. The features are unnormalized (at least the ones that require normalization using training set statistics). You would first split the dataset into, for example, a single train-val-test split OR into multiple cross-validation folds; then compute normalization statistics; and then normalize the features accordingly. This dataset includes both unlabeled examples (aka UNK) and the remaining labeled ones (all other labels) - see feature attribute 'label' after parsing an example from the TFRecord dataset. Includes an auxiliary table named "shards_tbl.csv" that describes the set of examples in the TFRecord dataset, with information about which file they are stored in (column 'shard'), and their order in the shard file (column 'example_i_tfrec').


Related Software

These data are associated with version v1.0.0 (ExoMiner++) of ExoMiner found under NASA GitHub.
DOI: 10.5281/zenodo.15466293
title: ExoMiner++: Enhanced Transit Classification and a New Vetting Catalog for 2-Minute TESS Data

description: Summary

This data repository is associated with the work presented in paper "ExoMiner++: Enhanced Transit Classification and a New Vetting Catalog for 2-Minute TESS Data" .

Contents



exominerplusplus_catalog_unk_tces_s1-s67_tess-spoc-2min_complete_1-16-2025_1014.csv: vetting catalog of unlabeled (UNK) TESS SPOC 2-min TCEs for sector runs S1-S67 (included multi-sector runs) produced using the ExoMiner++ models trained for the experiment "TESS+Kepler" (see Table 6 in paper). A shorter catalog is available online here (TCEs with score < 0.1 are excluded due to memory constraints).

exominerplusplus_catalog_labeled_tces_s1-s67_tess-spoc-2min_complete_1-14-2025_1039.csv: catalog for the labeled TESS SPOC 2-min TCEs for sector runs S1-S67 (included multi-sector runs) dataset used to train the models in the experiment "TESS+Kepler" (see Table 6 in paper).

exominer_plusplus_architecture.png: image of ExoMiner++ architecture.

tfrecords_tess-spoc-2min_s1-s67_9-24-2024_1159.tar.xz: a compressed file of the TESS dataset used to train and evaluate the models in the paper (does not include the Kepler data). The examples are split across multiple files (aka shards) in TFRecord format. This dataset was used as source for the creation of the cross-validation dataset used in the paper. The features are unnormalized (at least the ones that require normalization using training set statistics). You would first split the dataset into, for example, a single train-val-test split OR into multiple cross-validation folds; then compute normalization statistics; and then normalize the features accordingly. This dataset includes both unlabeled examples (aka UNK) and the remaining labeled ones (all other labels) - see feature attribute 'label' after parsing an example from the TFRecord dataset. Includes an auxiliary table named "shards_tbl.csv" that describes the set of examples in the TFRecord dataset, with information about which file they are stored in (column 'shard'), and their order in the shard file (column 'example_i_tfrec').


Related Software

These data are associated with version v1.0.0 (ExoMiner++) of ExoMiner found under NASA GitHub.
DOI: 10.7910/dvn/tbiopb
title: PDB: 6YE3, Interleukin-2 in complex with a mAb UFKA-20 (312K, 39°C, 100 ns)

description: IL-2 in complex with mAb UFKA-20 (312K, 39°C, 100 ns) . PDBs obtained every 50 ns.
DOI: 10.1594/pangaea.984675
title: Trace element composition of marine surface sediments of the Canadian Arctic

description: Concentrations of labile trace metals, including rare earth elements (REEs), were measured in the &lt;150 μm fraction of 141 terrestrial and marine surface sediment samples in the Canadian Arctic. This study evaluates the current state of metal contamination in the region using a geochemical survey coupled with pollution indices and sediment quality guidelines. Samples were collected during the ArcticNet 2016-2022 expeditions onboard the Canadian Coast Guard icebreaker Amundsen in the Canadian Arctic. The marine sediments were sampled with a box corer and the surface uppermost 1 cm of each box core was sampled. Geochemical data were measured with partial acid digestion and mass spectrometry.
DOI: 10.15468/dl.quayed
title: Occurrence Download

description: A dataset containing 916 species occurrences available in GBIF matching the query:
{
 "and" : [
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "TaxonKey is Saposhnikovia divaricata"
 ]
}

 The dataset includes 916 records from 37 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0007086-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.hcmdgq
title: Occurrence Download

description: A dataset containing 835 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Geometry POLYGON((96 26,99 26,99 30,96 30,96 26))",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "TaxonKey is Squamata"
 ]
}

 The dataset includes 835 records from 19 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0007088-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.yvujbx
title: Occurrence Download

description: A dataset containing 366 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Spermophilus xanthoprymnus"
 ]
}

 The dataset includes 366 records from 23 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0007089-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.17605/osf.io/dhrpb
title: DATA FOR: Do emotional carryover effects carry over?

description: Data and analysis code for: Masters,N, Lloyd, T and Starmer, C., 2024, Do emotional carryover effects carry over? Journal of Behavioral and Experimental Economics https://doi.org/10.1016/j.socec.2024.102312
DOI: 10.6084/m9.figshare.30704303
title: Supplementary Material for: Treatment of livedoid vasculopathy with the Janus Kinase inhibitors: A case series

description: Introduction: Livedoid vasculopathy (LV) is a rare chronic recurrent occlusive disease characterized by painful ulcers and atrophic porcelain-white scars. Owing to the lack of strict treatment guidelines, the commonly used traditional treatment methods are not effective in some patients. Therefore, there is an urgent need to develop new therapies for LV.
Case Presentations: Here we report four cases of LV that were successfully treated with the Janus kinase (JAK) inhibitors. The present study revealed a significant improvement in clinical activity and pain relief in patients with LV after the administration of abrocitinib (three patients) or upadacitinib (one patient). The median composite clinical score derived from erythema, ulceration, and physician-assessed pain fell from 7.25+0.25 at baseline to 4.50±0.50 at 4 weeks, 2.50±0.50 at 8 weeks and 1.00±0.707 at 12 weeks. The remission time ranged from 5 to 8 weeks, with a mean remission time of 6.75±1.258 weeks. Two patients experienced disease recurrence after the discontinuation of JAK inhibitor therapy. The average relapse time was 13.00±7.071 months after drug withdrawal. The mean follow-up period was 6.00±1.414 months. During the long follow-up period, only one patient showed a slight increase in the total cholesterol level, and no other adverse reactions were observed. Our study included one pediatric patient treated with upadacitinib. No adverse reactions occurred in this pediatric patient.
Conclusion: In conclusion, we believe that JAK inhibitors could be a promising therapeutic option for LV.
DOI: 10.6084/m9.figshare.30704303.v1
title: Supplementary Material for: Treatment of livedoid vasculopathy with the Janus Kinase inhibitors: A case series

description: Introduction: Livedoid vasculopathy (LV) is a rare chronic recurrent occlusive disease characterized by painful ulcers and atrophic porcelain-white scars. Owing to the lack of strict treatment guidelines, the commonly used traditional treatment methods are not effective in some patients. Therefore, there is an urgent need to develop new therapies for LV.
Case Presentations: Here we report four cases of LV that were successfully treated with the Janus kinase (JAK) inhibitors. The present study revealed a significant improvement in clinical activity and pain relief in patients with LV after the administration of abrocitinib (three patients) or upadacitinib (one patient). The median composite clinical score derived from erythema, ulceration, and physician-assessed pain fell from 7.25+0.25 at baseline to 4.50±0.50 at 4 weeks, 2.50±0.50 at 8 weeks and 1.00±0.707 at 12 weeks. The remission time ranged from 5 to 8 weeks, with a mean remission time of 6.75±1.258 weeks. Two patients experienced disease recurrence after the discontinuation of JAK inhibitor therapy. The average relapse time was 13.00±7.071 months after drug withdrawal. The mean follow-up period was 6.00±1.414 months. During the long follow-up period, only one patient showed a slight increase in the total cholesterol level, and no other adverse reactions were observed. Our study included one pediatric patient treated with upadacitinib. No adverse reactions occurred in this pediatric patient.
Conclusion: In conclusion, we believe that JAK inhibitors could be a promising therapeutic option for LV.
DOI: 10.6084/m9.figshare.30704306
title: Supplementary Material for: Paradoxical alopecia areata during biologic therapies: A case series and long-term follow-up

description: Alopecia areata (AA) is a non-scarring autoimmune alopecia that may arise as a paradoxical reaction (PR) during treatment with biologic agents for immune-mediated inflammatory diseases (IMIDs). Such PRs are increasingly recognized with the widespread use of biologics, particularly TNF-α inhibitors.
DOI: 10.6084/m9.figshare.30704306.v1
title: Supplementary Material for: Paradoxical alopecia areata during biologic therapies: A case series and long-term follow-up

description: Alopecia areata (AA) is a non-scarring autoimmune alopecia that may arise as a paradoxical reaction (PR) during treatment with biologic agents for immune-mediated inflammatory diseases (IMIDs). Such PRs are increasingly recognized with the widespread use of biologics, particularly TNF-α inhibitors.
DOI: 10.6084/m9.figshare.30704309
title: Supplementary Material for: Improved antitumor activity of IL-12-secreting CAR-T cells targeting CD176 across different carcinomas

description: Introduction
Effective therapeutic options for advanced solid tumors remain severely limited, causing high fatality rates especially after metastasis. The carbohydrate structure CD176 has been identified as a promising target for precise immunotherapy in multiple carcinomas, as it is present in about 90% of carcinomas but unavailable for binding on healthy tissue. Here, we report the development of CD176-specific 4th generation chimeric antigen receptor T cells (CAR-Ts), also known as TRUCKs (T cells redirected for antigen-unrestricted cytokine-initiated killing). To address the immunosuppressive tumor microenvironment (TME) and the heterogeneous antigen expression of solid tumors, which limit the efficacy of CAR-Ts, they were endowed with NFAT-inducible interleukin-12 (iIL12) release to improve pro-inflammatory autocrine and paracrine effects. 
Methods
The CD176-iIL12-TRUCK construct was tested for target specificity in a reporter cell assay using a JE6-1-derived reporter cell line. Afterwards, CD176-iIL12-TRUCKs were manufactured using primary CD8+ T cells. The influence of iIL12 on functionality of CD176-iIL12-TRUCKs, including T-cell activation levels, cytotoxic capacity and recruitment of bystander immune cells, was evaluated following co-cultures with CD176+ cell lines from different carcinomas. 
Results
Upon recognition of CD176+ cancer cell lines, CD176-iIL12-TRUCKs specifically released pro-inflammatory mediators (interferon-γ, tumor necrosis factor-α) and showed an increased activation marker expression (CD25, CD69). Using both a 7-AAD-based viability assay and an impedance-based cytotoxicity assay, elimination of CD176+ cell lines from different tumor entities by CD176-iIL12-TRUCKs was shown. Additionally, iIL12 released by CD176-iIL12-TRUCKs led to recruitment of monocyte and NK cell lines in a chemotaxis chamber assay. 
Discussion/Conclusion
Overall, the IL-12 release substantially improved effector functionality against CD176+ cells but not CD176- cells, indicating efficacy while maintaining specificity. Thus, CD176-iIL12-TRUCKs, with their potent anti-tumor efficacy and TME modulation potential, are a promising treatment option for patients with a variety of advanced solid tumors.
DOI: 10.6084/m9.figshare.30704309.v1
title: Supplementary Material for: Improved antitumor activity of IL-12-secreting CAR-T cells targeting CD176 across different carcinomas

description: Introduction
Effective therapeutic options for advanced solid tumors remain severely limited, causing high fatality rates especially after metastasis. The carbohydrate structure CD176 has been identified as a promising target for precise immunotherapy in multiple carcinomas, as it is present in about 90% of carcinomas but unavailable for binding on healthy tissue. Here, we report the development of CD176-specific 4th generation chimeric antigen receptor T cells (CAR-Ts), also known as TRUCKs (T cells redirected for antigen-unrestricted cytokine-initiated killing). To address the immunosuppressive tumor microenvironment (TME) and the heterogeneous antigen expression of solid tumors, which limit the efficacy of CAR-Ts, they were endowed with NFAT-inducible interleukin-12 (iIL12) release to improve pro-inflammatory autocrine and paracrine effects. 
Methods
The CD176-iIL12-TRUCK construct was tested for target specificity in a reporter cell assay using a JE6-1-derived reporter cell line. Afterwards, CD176-iIL12-TRUCKs were manufactured using primary CD8+ T cells. The influence of iIL12 on functionality of CD176-iIL12-TRUCKs, including T-cell activation levels, cytotoxic capacity and recruitment of bystander immune cells, was evaluated following co-cultures with CD176+ cell lines from different carcinomas. 
Results
Upon recognition of CD176+ cancer cell lines, CD176-iIL12-TRUCKs specifically released pro-inflammatory mediators (interferon-γ, tumor necrosis factor-α) and showed an increased activation marker expression (CD25, CD69). Using both a 7-AAD-based viability assay and an impedance-based cytotoxicity assay, elimination of CD176+ cell lines from different tumor entities by CD176-iIL12-TRUCKs was shown. Additionally, iIL12 released by CD176-iIL12-TRUCKs led to recruitment of monocyte and NK cell lines in a chemotaxis chamber assay. 
Discussion/Conclusion
Overall, the IL-12 release substantially improved effector functionality against CD176+ cells but not CD176- cells, indicating efficacy while maintaining specificity. Thus, CD176-iIL12-TRUCKs, with their potent anti-tumor efficacy and TME modulation potential, are a promising treatment option for patients with a variety of advanced solid tumors.
DOI: 10.6084/m9.figshare.30704312
title: Supplementary Material for: Evaluation of Disease Burden in Parkinson's Disease for Individuals Aged 60 and Older

description: OBJECTIVE: To evaluate global trends in Parkinson's disease (PD) burden (measured by disability-adjusted life years, DALYs) among individuals aged ≥60 years from 1990 to 2021, and project future trends to 2046.
METHODS: Using Global Burden of Disease (GBD) 2021 data, we analyzed age-standardized DALY rates (ASDR) via Joinpoint regression. Age-Period-Cohort (APC) modeling disentangled age, period, and birth cohort effects. Decomposition analysis quantified contributions of population growth, aging, and epidemiological changes. Bayesian APC (BAPC) projected DALYs to 2046.
RESULTS: Global PD DALYs increased from 2.55 million (95% UI: 2.33–2.79) in 1990 to 6.80 million (6.04–7.49) in 2021. ASDR rose annually by 0.31% (AAPC=0.31%, 95% CI: 0.29–0.33), with pronounced male predominance (male ASDR 2021: 861.9 vs female: 498.9; male-to-female ratio: 1.73). Highest ASDR occurred in High-middle SDI regions (683.7), lowest in Low SDI (612.9). APC analysis revealed disease risk peaked at ages 85–94 and increased with successive birth cohorts. Decomposition identified population growth as the primary driver of DALY increases (81.55% globally), exceeding contributions from aging (8.74%) and epidemiological shifts (9.71%). BAPC projections indicated rising absolute DALYs (+104% by 2046) but declining ASDR (607.3 by 2046), with widening gender disparities.
CONCLUSION: PD burden escalates globally due to demographic aging and population growth. Urgent international collaboration is needed for targeted interventions, particularly in high-burden regions and for older males.
DOI: 10.6084/m9.figshare.30704312.v1
title: Supplementary Material for: Evaluation of Disease Burden in Parkinson's Disease for Individuals Aged 60 and Older

description: OBJECTIVE: To evaluate global trends in Parkinson's disease (PD) burden (measured by disability-adjusted life years, DALYs) among individuals aged ≥60 years from 1990 to 2021, and project future trends to 2046.
METHODS: Using Global Burden of Disease (GBD) 2021 data, we analyzed age-standardized DALY rates (ASDR) via Joinpoint regression. Age-Period-Cohort (APC) modeling disentangled age, period, and birth cohort effects. Decomposition analysis quantified contributions of population growth, aging, and epidemiological changes. Bayesian APC (BAPC) projected DALYs to 2046.
RESULTS: Global PD DALYs increased from 2.55 million (95% UI: 2.33–2.79) in 1990 to 6.80 million (6.04–7.49) in 2021. ASDR rose annually by 0.31% (AAPC=0.31%, 95% CI: 0.29–0.33), with pronounced male predominance (male ASDR 2021: 861.9 vs female: 498.9; male-to-female ratio: 1.73). Highest ASDR occurred in High-middle SDI regions (683.7), lowest in Low SDI (612.9). APC analysis revealed disease risk peaked at ages 85–94 and increased with successive birth cohorts. Decomposition identified population growth as the primary driver of DALY increases (81.55% globally), exceeding contributions from aging (8.74%) and epidemiological shifts (9.71%). BAPC projections indicated rising absolute DALYs (+104% by 2046) but declining ASDR (607.3 by 2046), with widening gender disparities.
CONCLUSION: PD burden escalates globally due to demographic aging and population growth. Urgent international collaboration is needed for targeted interventions, particularly in high-burden regions and for older males.
DOI: 10.6084/m9.figshare.30704315
title: Supplementary Material for: An Alternate Method to Assess the Movement of Velum in a Clinical Setup

description: Introduction: Accurate evaluation of velum movement is important in the assessment of velopharyngeal function. Traditional phonation-based tasks can pose challenges for individuals with compromised phonatory subsystems. Identifying alternative, reliable tasks for visualizing velum movement is important for clinical assessment and intervention planning. The objective of the study is to determine whether a forced expiration task (FET) elicits greater velum movement compared to a phonation task (PT) during oral motor examination, using direct oral visualization.
Method: The study included 100 participants (50 males, 50 females) aged 18–70 years, excluding individuals with craniofacial anomalies, neurologic disorders, or conditions affecting velar function. Participants performed two tasks: phonation (“ah” repeated five times) and a FET (inhalation through the nose and forced exhalation through the mouth). Audio-video recordings were evaluated by three experienced speech-language pathologists using a 5-point scale for velum movement effectiveness. A Wilcoxon signed-rank test was used to compare scores between the two tasks. The Mann–Whitney U test was used to assess gender differences. Inter-rater reliability was evaluated using the intraclass correlation coefficient (ICC).
Results: Velum movement was significantly greater during FET compared to the PT (Z = -7.051, p &lt; 0.001), with a large effect size (r = 0.705). No significant gender differences were found for either task. Inter-rater reliability was moderate to good (ICC = 0.703).
Conclusion: The forced expiration task was more effective than the phonation task in producing visible velum movement during oral motor examination. This task may serve as a practical alternative in assessing patients with limited phonatory ability and may enhance clinical assessment protocols for velopharyngeal function.